Related Experiment Videos
[Cell therapy and prostate cancer]
Jean-Christophe Eymard1, J Bernard
1Unité fonctionnelle de recherche clinique et de thérapie cellulaire, Institut Jean-Godinot, 1. av du général Koenig, 51056 Reims, France. jc.eymard@reims.fnclcc.fr
Bulletin Du Cancer
|November 12, 2003
Summary
Dendritic cell vaccines show promise for advanced prostate cancer, offering a new therapeutic avenue beyond hormone therapy and chemotherapy. Further engineering of these immune cells may enhance vaccine response and clinical efficacy.
Area of Science:
- Immunology
- Oncology
- Cellular Therapy
Background:
- Hormone therapy is standard for advanced prostate cancer, but resistance and progression are inevitable.
- Chemotherapy offers limited palliative benefits; novel treatments are needed.
- Dendritic cells (DCs) are potent antigen-presenting cells with therapeutic potential.
Purpose of the Study:
- To review current dendritic cell-based vaccine strategies for advanced prostate cancer.
- To evaluate the efficacy and safety of existing DC vaccine approaches.
- To explore future directions for enhancing DC vaccine effectiveness.
Main Methods:
- Two main strategies: in vivo DC activation via cytokine gene-transduced cancer cells (e.g., GM-CSF) and ex vivo DC loading with tumor antigens.
- Clinical trials evaluated DCs loaded with prostate-specific membrane antigen (PSMA) or PAP-GM-CSF (Provenge).
- Patient cohorts included 130 for PSMA and 144 for PAP-GM-CSF.
Main Results:
- Allogeneic cancer cell administration and ex vivo loaded DC infusions were well tolerated.
- Treatments frequently induced weak, specific immune responses.
- Clinical efficacy of current DC vaccines remains limited.
Conclusions:
- Dendritic cell-based vaccines represent a promising immunotherapy for advanced prostate cancer.
- Current strategies show safety and induce immune responses, but clinical efficacy needs improvement.
- Engineering dendritic cells offers a pathway to amplify vaccine responses and enhance clinical outcomes.